José Gildo de Lima – Professor at the Department of Pharmaceutical Sciences – Universidade Federal de Pernambuco
Aline Cavalcanti de Lira – Pharmacist at Hospital das Clínicas – EBSERH – Universidade Federal de Pernambuco

Global Journal of Urology and Nephrology

With the changing age structure of the population, epidemiological shifts are observed. The incidence of infectious diseases has declined over the years and has been replaced by chronic diseases such as cardiovascular, cancer, diabetes mellitus, and psychological disorders. Anxiety disorders are more common among people suffering from chronic medical disease, and the number of medical illnesses is positively associated with the presence of anxiety (RAMOS; STANLEY, 2018, p.57).
Anxiety disorders are psychological disorders that have their basis in one of the most rudimentary and adaptive human functions: the innate stress response (‘fight or flight’’ response) (ABRAMOWITZ; DEACON, 2010, p. 104). So, it is possible that during our lifetime we may suffer some kind of anxiety disorder. In fact, the stress response is designed to motivate us to protect ourselves by preparing to cope with a perceived threat. But when this stress or fear is disproportionate to actual threat or danger and significantly interferes with normal daily functioning, the person is said to have an anxiety disorder (ABRAMOWITZ; DEACON, 2010, p.104, OLTHUIS; WATT; BAILE; HAYDEN; STEWART, 2015, p.12). While fear is the emotional response to an imminent threat, characterized by an acute autonomic system activation, anxiety is better described as the “anticipation of a future threat” (DONELLI; ANTONELLIA; BELLINAZZIB; GENSINIC; FIRENZUOLID, 2019, p. 2).
Anxiety is a disease which affects a large part of the world population. According to (Kessler et al (2007), approximately one in four individuals are likely to have, or have previously had, an anxiety disorder.

Keywords: ANXIETY

Free Full-text PDF

How to cite this article:
José Gildo de Lima, Aline Cavalcanti de Lira.ANXIETY. American Journal of Psychiatric Research and Reviews, 2020, 3:20. DOI: 10.28933/ajprr-2020-06-0505

1. ABRAMOWITZ, J. S.; DEACON, B. Anxiety and Its Disorders: Implications for Pharmacotherapy, Clinical Psychology Science and Practice, v. 17, n. 2 ,p. 104-106, June, 2010.
2. ANTONY, M. M. Recent advances in the treat-ment of anxiety disorders, Canadian Psycholo-gy, v. 52, n. 1, p. 1-9, Feb., 2011.
3. BANDELOW, B.; MICHAELIS, S.; WEDEKIND, D. Treatment of anxiety disorders, Dialogues Clinical Neuroscience, v. 19, n. 2, p. 93-107, June, 2017.
4. BELARMINO, Flávia Giselle Alexandrina. Perfil sociodemográfico de usuários de benzodiazepínicos na USF, mangueira II, Recife/PE. 2019. Trabalho de Conclusão de Residência (Curso de Residência Multiprofissional em Saúde da Família) – Universidade Federal de Pernambuco, Recife, 2019.
5. BRASIl. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de DST e Aids. Manual de adesão ao tratamento para pessoas vivendo com HIV e Aids, Brasília: Ministério da Saúde, 2008. 130 p.: il. (Série Manuais; n. 84). ISBN 978-85-334-0547-9.
6. CAMARGO; L. A., FILIPE, E. M. V.; CAPITÃO, C. G. Saúde mental, suporte familiar e adesão ao tratamento: associações no contexto HIV/Aids, Psico-USF, Bragança Paulista, v. 19, n. 2, p. 221-232, maio/ago., 2014.
7. CARVALHO, L. F. DIMENSTEIN, M. O modelo de atenção à saúde e o uso de ansiolíticos entre mulheres, Estudos de Psicologia, Natal, v. 9, n. 1, p. 121- 129, jan./abr., 2004.
8. CRASKE, M. G.; STEIN, M. B.; ELEY; T. C.; MI-LAD; M. R.; HOLMES; A.; RAPEE, R. M.; WITTCHEN, H. U. Anxiety disorders, Nature Re-views Disease Primers, v. 3, n. 17024, p. 1-18, May, 2017.
9. CRUZ, L. P.; VEDANA, K. G. G.; MERCEDES, B. P. C.; MIASSO, A. I. Dificuldades relacionadas à terapêutica medicamentosa no transtorno de ansiedade. Revista Eletrônica de Enfermagem (internet), Goiânia, v. 18, p. 1-10, mar., 2016. Disponível em
10. DONELLI, D.; ANTONELLIA; M. BELLINAZZIB; C.; GENSINIC, G. F.; FIRENZUOLID, F. Effects of lavender on anxiety: A systematic review and meta-analysis, Phytomedicine, v. 65, n. 153099, p. 1-31, Dec., 2019.
11. FARACH, F. J.; PRUITT, L. P.; JUNA, J. J.; JE-RUDA, A. B.; ZOELLNER, L. A.; ROY-BYRNE, P. P. Pharmacological treatment of anxiety dis-orders: Current treatments and future directions, Journal of Anxiety Disorders, v. 26, p. 833–843, Dec., 2012.
12. FEDOTOVA, J.; KUBATKAD, P.; BÜSSEL-BERGF, D.; SHLEIKINC, A. G.; CAPRNDAG, M.; DRAGASEKH, J.; RODRIGOI, L.; POHANKAJ, M.; GASPAROVAK , I.; NOSALL, V.; OPATRI-LOVAM, R.; QARADAKHIN, T.; ZULLIN, A.; KRUZLIAKM, P. Therapeutical strategies for anx-iety and anxiety-like disorders using plantderived natural compounds and plant extracts, Biomedi-cine & Pharmacotherapy, v. 95, p. 437–446, Nov. , 2017.
13. HILL, C.; WAITE, P.; CRESWELL, C. Anxiety disorders in children and adolescents, Paediat-rics and Child Health, v. 26, n.12, p. 548-553, Dec., 2016.
14. KARSNITZ; D. B.; WARD, S. Spectrum of Anxie-ty Disorders: Diagnosis and Pharmacologic Treatment, Journal of Midwifery & Women’s Health, v. 56, p. 266-281, May/June, 2011.
15. KESSLER, R. C.; ANGERMEYER, M.; JAMES C. ANTHONY, J. C.; GRAAF, R.; DEMYT-TENAERE, K; ISABELLE GASQUET, I; GIRO-LAMO, G.; GLUZMAN, S; GUREJE, O.; HARO, J. M.; KAWAKAMI, N.; KARAM, A.; LEVINSON, D.; MORA, M. E. M; BROWNE, M. A. O.; PO-SADA-VILLA, J.; STEIN, D. J.; TSANG, C. H. A.; AGUILAR-GAXIOLA, S.; ALONSO, J.; LEE, S.; HEERINGA, S.; PENNELL, BE.; BERGLUND, P.; GRUBER, M. J.; PETUKHOVA, M.; CHATTERJI, S.; ÜSTÜN, T. B. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization’s World Mental Health Survey Initiative, World Psychiatry, v. 6, n. 2, p. 168-176, June, 2007.
16. LIRA, A. C.; LIMA, J. G.; BARRETO, M. N. S. C.; MELO, T. M. A. G. Perfil de usuários de benzodiazepinicos no contexto da atenção primária à saúde, Revista de Atenção Primária de Saúde, Juiz de Fora ,v. 17, n.2, p. 223-228, abr/jun, 2014.
17. LOVE, A. S.; LOVE, R. Anxiety Disorders in Primary Care Settings (in press), Nursing Clinics of North America, n. 10, October, 2019. Re-trieved from ction/doSearch?occurrences=articleTitle&searchText=Anxiety+Disorders+in+Primary+Care+Settings&searchType=quick&searchScope=fullSite&journalCode=nuc.
18. MAHDI, M.; JHAWAR, S.; SOPHIED.BENNETT, S. D., SHAFRAN, R. Cognitive behavioral thera-py for childhood anxiety disorders: What hap-pens to comorbid mood and behavioral disor-ders? A systematic review, Journal of Affective Disorders, v. 251, p. 141-148, May, 2019.
19. NHI. Anxiety Disorders. Washington: National In-stitute of Mental Health. Department of Health and Human Services. Retrived from
20. NORDON, D. G.; AKAMINE, K.; NOVO, N. F.; HUBNER, C. V. K. Características do uso de benzodiazepínicos por mulheres que buscam tratamento na atenção primária, Revista de Psiquiatria do RS, Porto Alegre, v. 31, n.3, p. 152-158, set./dec., 2009.
21. OFORI-ASENSO, R; AGYEMAN, A. A. Irrational Use of Medicines—A Summary of Key Con-cepts, Pharmacy, v. 4, n. 35, p. 2-13, Oct., 2016.
22. OLTHUIS, J. V.; WATT, M. C.; BAILEY K.; HAY-DEN, J. A.; STEWART, S. H. Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults, Cochrane Data-base of Systematic Reviews, n. 3, Art. No.: CD011565, p. 1-172, 2015.
23. PULL, Lauren. Étude de la prise en charge des troubles anxieux par les médecins generalistes au Luxembourg, 2009. Tese (Doutorado em Médecine Génerale) – Faculté de Médecine Pierre et Marie Curie, Université Pierre et Marie Curie , Paris, 2009.
24. RADAN, C. Benzodiazépines, du traitement au sevrage, Actualités Pharmaceutique, v. 56, n. 564, p. 46-48, mars, 2017.
25. RAMOS, K; MELINDA A. S. Anxiety Disorders in Late Life, Psychiatric Clinics of North America, v. 41, n. 1, p. 55-64, Dec., 2018.
26. SANTA CATARINA (Estado). Transtorno de Ansiedade: protocolo clínico. Santa Catarina: SUS, 2015, 1p. Disponível em
27. SARTORI, S. B.; SINGEWALD, N. (in press) Novel pharmacological targets in drug develop-ment for the treatment of anxiety and anxiety-related disorders. Pharmacology & Therapeutics. Retrieved from
28. SHADER, R. I.; GREENBLATT, D. J. Drug thera-py: use of Benzodiazepines in anxiety disorders, The New England Journal of Medicine, v. 328, n. 19, p.1398-1405, May, 1993.
29. SILVEIRA, L. M. Cruz; RIBEIRO, V. M. B. Grupo de adesão ao tratamento: espaço de “ensinagem” para profissionais de saúde e pacientes. Interface-Comunicação, saúde, educação, Botucatu, v. 9, n. 16, p. 91-104, set./fev., 2005.
30. SOUSA, L. P. C.; VEDANA, K. G. G.; MIASSO, A. I. Adesão ao tratamento medicamentoso por pessoas com transtorno de ansiedade, Cogitare Enfermagem, v. 21, n. 1, p. 01-11, jan./mar, 2016.
31. TANG, F.; WANG, G.; LIANC, Y. Association be-tween anxiety and metabolic syndrome: A sys-tematic review and meta-analysis of epidemio-logical studies, Psychoneuroendocrinology, v. 77, p. 112-121, Mar, 2017.
32. TAVARES, N. U. L.; BERTOLDI, A. D.; MENGUE, S. S; ARRAIS, P. S. D.; LUIZA, V. L.; OLIV.EIRA, M. A. V., LUIZ ROBERTO RAMOS, L. R. R.; FARIAS, M. R.; DAL PIZZO, T. S. Fatores associados à baixa adesão ao tratamento farmacológico de doenças crônicas no Brasil, Revista de Saúde Pública, São Paulo, v. 50 (supl 2), p.1s-11s, 2016.
33. TECOTT, L. H. Designer genes and anti-anxiety drugs, Nature Neuroscience, v. 3, n. 6, p. 529-530, June, 2000.
34. WOLITZKY-TAYLOR, K. B.; CASTRIOTTA, N.; LENZE, E. J.; STANLEY, M. A.; CRASKE, M.G. Anxiety disorders in older adults: a comprehen-sive review, Depression and Anxiety, v. 27, n. 2, p. 190-211, Feb., 2010.